Late-Stage Lung Cancer Patients Eligible for Surgical Biopsies

Share this content:

the Cancer Therapy Advisor take:

Since surgical biopsies are too dangerous for patients with late-stage lung cancer, less invasive approaches, such as fine needle aspiration and core needle biopsies, are often used. Unfortunately, lead author of a study published in The Journal of Thoracic and Cardiovascular Surgery, David T. Cooke, MD, said these procedures may not collect enough cells for molecular testing.


According to the study, insufficient tumor tissue is available for molecular analysis, which is a common problem in advanced lung cancer treatment. This tumor tissue is needed before doctors can prescribe targeted therapy.


Cooke and colleagues discussed the cases of 25 patients with known or suspected stage IV lung cancer at a multidisciplinary thoracic oncology conference or clinic. They examined their records, and all patients underwent surgical biopsies, with a majority being video-assisted thoracic surgery.


For 19 of the 25 patients, potentially targetable molecular information was identified. Ten patients were also eligible to enroll in a therapeutic targeted clinical trial. In addition, five patients experienced complications, in which three were minor, during surgery.


Cooke said that patients whose less invasive biopsies were deemed unsuccessful and whose cases were reviewed in a multidisciplinary manner could be candidates for surgical biopsies.


The multidisciplinary team, according to Cooke, should include a pulmonologist, radiologist, surgeon, and medical oncologist.

Late-Stage Lung Cancer Patients Eligible for Surgical Biopsies
Late-Stage Lung Cancer Patients Eligible for Surgical Biopsies

Researchers at University of California, Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).

The findings, to be published in the July issue of The Journal of Thoracic and Cardiovascular Surgery, address a common problem in treatment for advanced lung cancer: insufficient tumor tissue available for molecular analysis, which is required before prescribing targeted therapy.


Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs